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Abstract
Background: The psychometric properties of an instrument should be evaluated routinely when using different
samples. This study evaluated the psychometric properties of the Functional Assessment of Cancer Therapy-General
(FACT-G) when applied to a sample of Brazilian cancer patients.
Methods: The face, content, and construct (factorial, convergent, and discriminant) validities of the FACT-G were
estimated. Confirmatory factor analysis (CFA) was conducted the ratio chi-square by degrees of freedom (χ2/df), the
comparative fit index (CFI), the Tucker-Lewis index (TLI), and the root mean square error of approximation (RMSEA)
as indices. The invariance of the best model was assessed with multi-group analysis using the difference of chi-squares
method (Δχ2). Convergent validity was assessed using Average Variance Extracted (AVE) and discriminant validity was
determined via correlational analysis. Internal consistency was assessed using the Cronbach’s alpha (α) coefficient, and
the Composite Reliability (CR) was estimated.
Results: A total of 975 cancer patients participated in the study, with a mean age of 53.3 (SD = 13.0) years. Of these
participants, 61.5 % were women. In CFA, five correlations between errors were included to fit the FACT-G to the
sample (χ2/df = 8.611, CFI = .913, TLI = .902, RMSEA = .088). The model did not indicate invariant independent samples
(Δχ2: μ: p < .001, i: p < .958, Cov: p < .001, Res: p < .001). While there was adequate convergent validity for the physical
well-being (AVE = .54) and social and family Well-being factors (AVE = .55), there was low convergent validity for the
other factors. Reliability was adequate (CR = .76–.89 and α = .71–.82). Functional well-being, emotional well-being, and
physical well-being were the factors that demonstrated a strong contribution to patients’ health-related quality of life
(β = −.99, .88, and .64, respectively).
Conclusion: The FACT-G was found to be a valid and reliable assessment of health-related quality of life in a Brazilian
sample of patients with cancer.
Keywords: Cancer, Validity, Reliability, Brazil, Health-related quality of life
* Correspondence: jucampos@fcfar.unesp.br
1Departamento de Alimentos e Nutrição. Faculdade de Ciências
Farmacêuticas de Araraquara, UNESP-Univ Estadual Paulista, Rod.
Araraquara-Jaú, km 01, Araraquara, São Paulo, Brazil
Full list of author information is available at the end of the article
© 2016 Campos et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Campos et al. Health and Quality of Life Outcomes  (2016) 14:8 
DOI 10.1186/s12955-015-0400-8
Background
Health-related quality of life (HRQOL) is a concept that
has assumed an important role in clinical practice [1–7]
and research aimed at cancer patients [3, 8, 9]. The
disorganization of the HRQOL of patients with cancer
can have a significant negative impact on treatment re-
sponse, symptoms associated with the disease/treatment,
disease prognosis, and the development of unpleasant
concomitant clinical conditions. The improvement of
procedures and diagnostic techniques as well as the var-
iety of available treatment modalities have led to in-
creased life expectancy in cancer patients, leading to
greater concern about their long-term well-being [10].
Thus, when choosing between available therapies, the
oncologist’s decision-making is driven not only by the ef-
fectiveness of the treatment, but also by its impact on
HRQOL [11].
However, since HRQOL is a latent variable, (i.e., not dir-
ectly measurable), many instruments have been developed
to evaluate it in the general population (e.g., World Health
Organization Quality Of Life Assessment [WHOQOL-100]
[12–16], Medical Outcomes Study SF - 36-Short
Form Health Survey [17, 18], and the Sickness Impact
Profile [19]).
Given the increase in generic measures for assessing
HRQOL, there is a need for instruments that are specific
to individuals’ clinical conditions and that consider asso-
ciated disabilities, limitations, and symptoms specific to
each condition. Among the instruments proposed in the
literature to assess HRQOL in cancer patients, the two
most frequently used instruments used worldwide are
the Cella et al.’s Functional Assessment of Cancer
Therapy-General (FACT-G) [10] and the European
Organization for Research and Treatment of Cancer-
Quality of Life Questionnaire Core 30 (EORTC QLQ-
C30) [20].
Initially published in 1993 in the United States, the
FACT-G, first has been translated into more than 30
languages [21]. To determine its suitability for use in dif-
ferent countries and samples, a number of validation
studies have been conducted [10, 22, 23].
Despite the existence and widespread application of a
Portuguese version of the FACT-G, only one study [24]
has evaluated the psychometric properties of this instru-
ment. However, this study was limited to evaluation of
the FACT-G psychometric properties in a sample of in-
dividuals with cervical cancer.
Moreover, it is important to note that despite the fact
that existing literature [10, 25] indicates that the FACT-
G is appropriate for use in oncology, easy to use, con-
cise, and responsive to clinical changes, its psychometric
properties should be routinely evaluated when applied to
different samples. Specifically, this should occur because
of knowledge that these properties are unrelated to the
instrument itself, but rather to the sample, and is
thereby directly influenced by the sample’s character-
istics [26].
Thus, we performed this study to evaluate the psycho-
metric properties of the FACT-G when applied to a large
sample of Brazilian cancer patients.
Methods
Study design and sampling
The present study employed a cross-sectional design. A
total of 1099 cancer patients from the outpatient clinic
and in the hospitalization sector of the Barretos Cancer
Hospital were invited to participate in this study during
2013.
The estimated minimum sample size was based on
Hair et al.’s [27] recommendation of 5–10 subjects (k)
for each model parameter. Since the tested model has 58
parameters (FACT-G: 27 items, 27 errors, and 4 factors),
we estimated that 290–580 subjects would be required.
As the study also evaluated the invariance of the instru-
ment for independent samples, it was necessary to use a
second sample of the same size. Thus, the minimum
sample size needed to conduct the required analysis was
between 580 and 1160 participants. However, since an-
other objective was to explore the psychometric proper-
ties of the FACT-G for the population of cancer patients
in Brazil, the sample had to be large enough to conveni-
ently capture the population’s variability. Consequently,
we chose to analyze data from a representative sample
of 1020 participants.
The exclusion criteria for participants were as follows:
had undergone a surgical procedure, had been diagnosed
with cognitive impairment, were undergoing palliative
care, had been diagnosed with a severe psychiatric dis-
order, and under 18 years of age. We included all adult
patients who agreed to participate, regardless of cancer
diagnosis, treatment type and clinical stage, as well as
having no previously reported exclusion characteristics.
Study variables and measures
To characterize the sample, we collected socio-
demographic and clinical information (Table 1). It is
important to clarify that the socio-economic class and
household head education level were classified ac-
cording to the Associação Brasileira de Empresas de
Pesquisa (ABEP) [28], and that clinical information
about the disease was obtained by consulting the pa-
tient’s chart.
The height (cm) and weight (kg) reported by patients
were recorded for the calculation of body mass index
(kg/m2) (BMI) and the subsequent classification of their
nutritional status. For BMI classification, we used the
adult cutoff points (>20 years) proposed by the World
Health Organization [29].
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The average age of the 1020 participants was 53.3
(SD = 13.0) years, and all had an established cancer
diagnosis.
It is important to highlight that not all patients an-
swered all questions on the socio-demographic inven-
tory, and that some patients’ charts did not contain
some clinical information. Additionally, it should be
clarified that the lowest response rate was for informa-
tion about clinical stage (88.0 %), which was related to
the clinical difficulty of establishing such precise stage-
related information rather than a lack of information in
the medical record. However, since response rates for
socio-demographic variables (98.5–100.0 %) and clinics
(98.6–100 %) were high (with the exception of clinical
stage), this does not represent a study limitation.
HRQOL was estimated using the FACT-G [10]. The
FACT-G was first published in 1993 in the United States
and was developed based on structured interviews with
oncology experts and cancer patients. The use of instru-
ment was proposed following five years of development
and psychometric assessments [10]. Factor analysis of
the instrument, originally developed to consist of 28
items, revealed the following five factors [10].
In 1999, Webster et al. [21] conducted a study in
mixed sample of cancer patients (n = 99), and proposed
the removal of one factor (“Relationship with the
Table 1 Socio-demographic and clinical characterization of participantsa
Socio-demographic characteristics n % Clinical characteristic n %
Gender Specialty
Male 375 38.5 Head and neck 73 7.5
Female 600 61.5 Higher digestive tract 94 9.6
Religion Lower digestive tract 200 20.5
No 40 4.2 Gynecology 107 11.0
Yes 922 95.8 Hematology 4 .4
Religious Practice Breast Cancer 297 30.5
No 139 14.5 Brain tumor 14 1.4
Yes 822 85.5 Orthopedic 24 2.5
Marital status Skin 41 4.2
Single 139 14.3 Thorax 48 4.9
Married 631 64.8 Urology 73 7.5
Widowed 99 10.2 Clinical stage
Separated/Divorced 104 10.7 I 72 8.4
Working II 215 25.1
No 716 73.6 III 333 38.8
Yes 257 26.4 IV 237 27.7
Economic class Treatment type
A 24 2.4 Chemotherapy 616 63.4
B 334 34.3 Radiotherapy 163 16.8
C 462 47.4 Chemotherapy and radiotherapy 148 15.2
D and E 155 15.9 Hormone therapy 26 2.7
Data collection place Immunotherapy 18 1.9
Outpatient 29 3.0 Metastasis
Hospitalization units 940 97.0 No 599 61.8
Yes 370 38.2
Body Mass Index (kg/m2)
<18.5 (Low weight) 57 5.9
18.5├25.0 (Eutrophic) 407 42.3
25.0├30.0 (Pre obesity) 310 32.2
≥30.0 (Obesity) 188 19.5
a%: were calculated for each variable, considering the total number of responders and non-participants
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doctor”) and its associated items. This decision was
made after evaluation of cultural adaptations of the in-
strument, patient feedback, and statistical analysis using
item response theory (IRT). However, one additional
item was added (“I am concerned that my condition will
get worse”). Based on these findings and proposals, the
current FACT-G is now in its fourth version.
Thus, in this study, we used the fourth version of the
instrument proposed by Webster et al. [21], which is
comprised of 27 items divided into four factors (physical
well-being, social and family well-being, emotional well-
being, functional well-being) in a reflexive model. All
items are rated using a 5-point Likert scale response for-
mat (0 = Not at all, 4 = Very much). Two factors are for-
mulated in the positive direction and two in the negative
direction. One item in the emotional well-being dimen-
sion presents a reversed response scale relative to the
other items for the same factor. In this study, we used
the Portuguese version of the FACT-G, which was pro-
vided and authorized by the Functional Assessment of
Chronic Illness Therapy (FACIT) Group.
The non-response rate to FACT-G items (missing
data) ranged from 0.1 to 0.6 % with the exception of
item 14, which had an extremely high non-response rate
(45 %). Considering this item refers to “satisfaction with
sex life” and the literature has reported that participants
infrequently respond to this item [30] and that FACIT
permits its exclusion, we decided to remove this item
from the analysis. Additionally, since the sample had an
expanded size, it was decided to exclude individuals who
did not respond to one or more of the other instrument
items (listwise). Thus, the final sample consisted of 975
participants (mean age: 53.3 years, SD = 13.0) (Table 1).
In this study, we also used the EORTC QLQ-C30 to es-
timate the concurrent validity of the FACT-G. Therefore,
it should be clarified that used the original factorial pro-
posal for the EORTC QLQ-C30 consists of nine first order
factors (Physical, Role, Emotional, Cognitive and Social
functioning, Fatigue, Nausea and vomiting, Pain, Overall
Quality of Life - global score) and 5 single terms grouped
together into a factor referred to as “Spurious.” The fit
of this version to sample was adequate (χ2/df = 3071;
Comparative Fit Index [CFI] = .968; Tucker-Lewis index
[TLI] = .961; root mean square error of approximation
[RMSEA] = .046).
Transcultural adaptation of the FACT-G
Face validity
To analyze face validity, we used the guidelines proposed
by Guillemin et al. [31] and Beaton et al. [32].
The instrument translation was independently per-
formed by three bilingual translators who were native
Portuguese speakers and had knowledge and experience
in an English-speaking country. This study’s researchers
evaluated translations in order to obtain a consensus for
a single Portuguese version. This version was back-
translated by a bilingual individual who was a native
English speaker. The final Portuguese version was then
evaluated by a team of three teachers and three Portu-
guese oncology experts to ensure that the semantic,
idiomatic, cultural, and conceptual aspects of the instru-
ment were comparable to those of the original version.
Our final version was compared to the original version
of the instrument and to the original Portuguese version
proposed by the FACIT Group. It was not necessary to
alter the Portuguese version presented by FACIT.
To calculate the misunderstanding index (MI) of each
item, the FACT-G was administered to the same 32 can-
cer patients in interview form. No items presented a
MI > 10 %; thus, it did not require reformulation.
Content validity
The content validity of the FACT-G was estimated using
the Content Validity Ratio (CVR) proposed by Lawshe
[33]. In this stage, 12 judges/experts in the field of on-
cology/nutrition rated each item according to its essenti-
ality. To evaluate the CVR, we used Wilson et al.’s [34]
proposal of α = 5 % (CVR12; 0.05 ≥ 0.57).
Evaluation of psychometric characteristics
To evaluate the psychometric sensitivity of the items,
summary and shape measures were estimated. Items with
absolute values of skewness (Sk) and kurtosis (Ku) greater
than 3 and 7, respectively [26], were considered to present
a severe violation of normality. Multivariate outliers were
identified using Mahalanobis distance [35, 36].
The construct validity of the instrument was estimated
by measuring factorial, convergent, and discriminant val-
idity. We conducted confirmatory factor analysis (CFA)
using the matrix of polychoric correlations and the
Weighed Least Squares Mean and Variance Adjusted
(WLSMV) using MPLUS 6.12 software (Muthén &
Muthén, Los Angeles, CA). To evaluate the goodness of
fit, we used as the ratio chi-square by degrees of free-
dom (χ2/df ), CFI, TLI, and RMSEA as indices [35]. The
model’s fit was considered adequate when χ2/df ≤ 2.0,
CFI and TLI ≥ .9, and RMSEA ≤ .08 [27, 35].
Items that had factor weights (λ) < .40 were removed,
as well as those that were redundant by the modification
indices estimated by the Lagrange multipliers (LM)
method (LM > 11, p < .001). The modification indices
were also used to verify the correlation between the item
errors [35].
The invariance of the best model was assessed with
multi-group analysis using the difference of chi-squares
method (Δχ2). Here, the sample was randomly divided
into two parts (6:4), where 60 % comprised the “Test
Sample” and 40 % the “Sample Validation.” Multi-group
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analysis used to conduct the invariance test, using the
chi-square difference (Δχ2) between the model with free
factorial weights and the model with equal weights. If
the hypothesis of the factorial weight’s invariance was
acceptable (metric invariance), then analyses of the inter-
cepts’ invariance (scalar invariance) and residual’s vari-
ances/covariances invariance (structural invariance) were
conducted [26, 37].
Correlation analysis between the factors of the FACT-G
and EORTC QLQ-C30 were used to estimate the
concurrent/divergent validity. The concurrent validity is de-
termined by a front moderate to strong correlation between
theoretically similar factors and divergent validity by a front
of weak correlations among theoretically distinct factors.
Convergent validity was assessed using the Average Vari-
ance Extracted (AVE) [35, 38] and values of AVE ≥ .50 were
considered adequate [27]. Discriminant validity was estimated
by calculating the correlations between the factors and was
considered adequate when AVEi and AVEj ≥ ρij
2 [26, 35, 38].
We assessed internal consistency using Cronbach’s
standardized alpha coefficient (α) and Composite
Reliability (CR). Internal consistency was considered
adequate when α ≥ .70 [39] and CR ≥ .70 [27].
After defining the best model, we explored the pres-
ence of a significant correlation between the factors.
Subsequently, based on the theoretical justification for
evaluation of a higher order factor, we developed a sec-
ond order hierarchical model (SOHM).
The analyses were performed using SPSS version 22.0
(IMB, Chicago, IL) and MPLUS 6.12 (Muthén & Muthén,
Los Angeles, CA) programs.
Ethical considerations
The present study was approved by the Research in
Humans Ethics Committee of the Cancer Hospital of
Barretos (protocol 561/2011). Only patients who agreed
and signed the informed consent form participated in
the study.
Table 2 Summary and shape measures and the content validity ratio of the items
FACT-G Mean Median Mode Standard-deviation Skewness Kurtosis CVRa
FACT1 .83 0 0 1.14 1.19 .34 .50
FACT2 .50 0 0 .96 2.04 3.37 .17
FACT3 .50 0 0 1.01 2.02 3.04 -.33
FACT4 .90 0 0 1.14 1.02 -.04 1.00b
FACT5 .66 0 0 1.14 1.63 1.41 .67b
FACT6 .43 0 0 .86 2.03 3.39 .33
FACT7 .56 0 0 1.08 1.79 1.92 .00
FACT8 2.98 3 3 1.06 −1.17 .95 .00
FACT9 3.49 4 4 .72 −1.69 3.81 .50
FACT10 3.12 3 4 .99 −1.30 1.49 .50
FACT11 3.19 3 3 .80 −1.59 4.23 −.33
FACT12 3.43 4 4 .73 −1.94 6.19 −.33
FACT13 3.59 4 4 .57 −1.64 5.68 .33
FACT14 2.46 3 3 1.28 −.68 −.62 .33
FACT15 .79 0 0 1.13 1.28 .51 .67b
FACT16 .71 1 1 .67 1.32 4.66 .33
FACT17 .20 0 0 .65 3.63 13.14 .83b
FACT18 .60 0 0 1.05 1.75 2.02 .17
FACT19 .30 0 0 .85 3.02 8.36 .33
FACT20 .56 0 0 1.06 1.89 2.45 .50
FACT21 2.39 3 3 1.20 −.54 −.59 .33
FACT22 2.73 3 3 1.12 −1.17 .79 −.17
FACT23 3.02 3 3 .91 −1.11 1.47 .17
FACT24 3.08 3 3 .78 −1.77 5.40 .67b
FACT25 2.62 3 3 1.15 −.96 .21 .50
FACT26 3.05 3 3 .75 −1.54 4.76 .17
FACT27 3.01 3 3 ,83 −1.17 2.50 .83b
a CVR12; 0.05 = 0.57;
b values above the significant value (essential items)
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Results
The adherence rate was 92.8 %. The reasons for non-
adherence to the study were lack of time (n = 5), having
participated in another study on the same day (n = 1),
shyness (n = 2), not feeling well (n = 3), refusal to
complete the socio-demographic questionnaire (n = 1),
no justification (n = 7), and reluctance to participate be-
cause data were to be collected via interview (n = 60).
Among participants, there was a higher prevalence of
women as well as individuals with religious practice and
those who were married, working, had breast and lower
digestive tract cancer, were undergoing chemotherapy,
and without metastasis (Table 1).
The summary measures of participants’ answers on
the FACT-G and the CVR are presented in Table 2.
The only item that presented psychometric sensitivity
issues was item 17 (“losing hope in the fight”). We no-
ticed that the judges/experts indicated that only 6 items
were considered essential to assessment of the impact of
disease/treatment on the HRQOL of cancer patients.
Fig. 1 Factor structure of the refined model of the Functional Assessment of Cancer Therapy. λ = .43 to .90; χ2/df = 8.611, Comparative fit index (CFI)
= .913, Tucker-Lewis index (TLI) = .902, Root mean square error of approximation (RMSEA) = .088 fitted to the sample of Brazilian cancer patients
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The factor structure of the FACT-G showed unsatisfac-
tory fit to the sample (λ = .43 to .92; χ2/df = 13.313, CFI
= .857, TLI = .841, RMSEA = .112). Following the modifi-
cation indices, five correlations were inserted between the
errors (e8–e10, e11–e12, e12–e13, e19–e20, e21–e22).
The factor structure of the refined model fit the
sample (Appendix) (λ = .43 to .90; χ2/df = 8.611, CFI = .913,
TLI = .902, RMSEA = .088) and is presented in Fig. 1.
The fit of the refined model was adequate for the test
sample (λ = .42 to .89; χ2/df = 5.034, CFI = .914, TLI = .903,
RMSEA = .083) and for the validation sample (λ = .40 to
.89; χ2/df = 4.436, CFI = .916, TLI = .905, RMSEA = .094).
The model was not invariant for independent samples
(Δχ2: μ: p < .001, i: p < .958, Cov: p < .001, Res: p < .001).
We observed low convergent validity for emotional well-
being (AVE= .35), and functional well-being (AVE= .42). The
AVE presented adequate values for physical well-being (AVE
= .54) and social and family well-being factors (AVE= .55).
The reliability was adequate (CR= .76–.89 and α= .71–.82).
Based on the significant correlations between the pri-
mary factors (Fig. 1) and the theoretical justification of
drafting a final construct built from the four primary fac-
tors, a SOHM was constructed.
The fit of the SOHM to the sample (λ = .44 to .90; χ2/
df = 8.708, CFI = .911, TLI = .901, RMSEA = .089) is pre-
sented in Fig. 2.
It is noteworthy that the following factors made a great
contribution to the operationalization of the HRQOL
Fig. 2 Factor structure of the second order hierarchical model of the Functional Assessment of Cancer Therapy. λ= .44 to .90; χ2/df = 8.708, Comparative fit
index (CFI) = .911, Tucker-Lewis index (TLI) = .901, Root mean square error of approximation (RMSEA) = .089 fitted to the sample of Brazilian cancer patients
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construct: Functional Well-being (β = −.985), Emotional
Well-being (β = .881), and Physical Well-being (β = .641).
The correlation matrix between the FACT-G and EORTC
QLQ-C30 factors is presented in Table 3. Adequate validity
concurrent/divergent of FACT-G was found. Specifically,
there were high correlations between theoretically similar
factors, and low correlations between different factors.
Discussion
This study tested and determined the validity and reliabil-
ity of the FACT-G when applied to a sample of Brazilian
cancer patients.
The FACT-G is a widely used instrument in clinical
practice for the evaluation of cancer patients. This study
presented an evaluation of the instrument’s factor struc-
ture when applied to a large Brazilian sample, providing
professionals with information about the steps neces-
sary to evaluate its psychometric properties and the
quality of the information that can be obtained from it.
To ensure that the structure of the FACT-G was ad-
equate for the sample, one item was removed (item 14).
In particular, item 14 pertains to the patient’s satisfaction
with his/her sex life, and is therefore characterized as a
very specific item that reflects the interviewee’ intimacy.
As a result, the non-response rate was 45 %, which pre-
vented its inclusion in the evaluation of the total sample.
This finding was also observed by Dapueto et al. [40].
The FACIT Group suggests that if the participant does
not feel comfortable responding to this item, he/she
should not respond to this item and the interviewer
should move to the next item. Regarding the inclusion
of the correlations between the errors (LM > 11), this
can be justified by the theoretical proximity of the items.
It is also clear that, although item 17 presented prob-
lems with regard to psychometric sensitivity, the same fac-
torial structure presented adequate weight. Furthermore,
the importance of its theoretical content justifies its reten-
tion for the purpose of maintaining the structure of the
FACT-G. This item assesses the “hope of the individual in
the fight against disease” and, as was already reported by
Shinn et al. [41], is an important aspect of HRQOL.
Additionally, it is necessary to address the issue of the
CVR (Table 2), as the experts only considered six FACT-G
items to be essential. This raises the questions of the
judges’ actual experience evaluating HRQOL, since the
FACT-G was developed by a group of experts and is
widely accepted at national and international levels. Thus,
despite the judges’ responses in terms of items related to
the construct, perhaps their knowledge is specific to par-
ticular types of cancer, leading to the determination that
some instrument items were nonessential.
This study also presents a hierarchical model of the
FACT-G that shows the contribution of each factor in
building the central concept evaluated by the instrument.
Specifically, results indicated that physical, emotional and
functional well-being had a greater contribution to the con-
struct formulation (Fig. 2). This may have been related to
the high toxicity of treatments (chemotherapy and radio-
therapy) and the severity of the disease, which impact pa-
tients’ physical quality of life, and consequently affect
physical, functional, and emotional factors. Therefore, this
should be taken into account in the approach used and/or
Table 3 Correlation’s matrix of factors of the FACT-G and EORTC QLQ-C30 (version fitted to the sample)
FACT-G EORTC QLQ-C30
Factorsa PWB SFWB EWB FWB QL PF RF EF CF SF FA NV PA SPUR
FACT-G PWB 1
SFWB -.17 1
EWB .61 -.38 1
FWB -.65 .57 -.75 1
EORTC QLQ-C30 QL -.61 .34 -.53 .73 1
PF .87 -.14 .45 -.64 -.46 1
RF .79 -.07 .44 -.70 -.49 .92 1
EF .60 -.26 .90 -.51 -.47 .47 .46 1
CF .49 -.21 .46 -.34 -.27 .47 .49 .42 1
SF .46 -.24 .45 -.62 -.55 .47 .54 .50 .34 1
FA .92 -.08 .55 -.58 -.51 .82 .81 .51 .59 .43 1
NV .98 .01 .28 -.27 -.23 .43 .48 .32 .30 .21 .61 1
PA 1.00 -.12 0.42 -.47 -.44 .58 .61 .48 .42 .38 .68 .32 1
SPUR .93 -.16 .58 -.71 -.47 .81 .78 .62 .65 .36 .98 .84 .68 1
aFACT-G: PWB physical well-being, SFWB social family well-being, EWB emotional well-being, FWB functional well-being; EORTC QLQ-C30: QL overall quality of life
(global score), PF physical functioning, RF role functioning, EF emotional functioning, CF cognitive functioning, SF social functioning, FA fatigue, NV nausea and
vomiting, PA pain, SPU spurious (single terms)
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professional management of such patients. These factors
also had higher correlation coefficients in front of the
EORTC QLQ-C30 including the quality of life (global) fac-
tor that aims for the same supremacy in term the impact of
disease and treatment on patients’ HRQOL (Table 3).
Another aspect we found was the lack of invariance in
the model when fitted to different samples. This provides
a warning that, although changes in sample characteristics
may not interfere with the model fit, they may interfere
with the operationalization of the construct. Conse-
quently, professionals who use this tool must know the
psychometric properties of the instrument in reference to
the specific sample to be evaluated.
A limitation of this study may be the adoption of a non-
probabilistic sampling design, which inevitably exerted in-
fluence on sample characteristics. However, this strategy
has been commonly utilized in validation studies. The use
of sufficient sample size ensures credibility in the
decision-making resulting from the statistical tests. Thus,
it is suggested that structural model we have presented be
tested in other samples, with different clinical and socio-
demographic characteristics to confirm its stability and
increase its representativeness. The lack of test-retest reli-
ability could also be cited as a limitation. However, it
should be considered that among patients with cancer,
HRQOL may change in a short period depending on the
treatment type and diagnosis. Consequently, this could
skew the reproducibility of analyses. Thus, to evaluate this
possibility, we suggest conducting a follow-up study. It is
only by doing so that accurate evidence related to the
temporal stability of the FACT-G can be obtained.
Another suggestion for future studies is to use ITR as
an analytical strategy to complement traditional analyses
(such as those presented in this study). The use of IRT
could provide information regarding item construction,
local independence, and the individual profile related to
impact on HRQOL.
Conclusion
The FACT-G was found to be a valid and reliable assess-
ment of HRQOL in a Brazilian sample of cancer pa-
tients. It is important to note that, similar to the present
study, the structure of the FACT-G should be evaluated
when the sample or cultural context have distinct char-
acteristics. This will ensure that the instrument will col-
lect valid and reliable data suitable for each sample type.
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